Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 19/20 | 0.70 |
| ▸ | BCR | P11274 | 16/20 | 0.70 |
| ▸ | KIT | P10721 | 10/20 | 0.70 |
| ▸ | ABL2 | P42684 | 5/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.70 |
| ▸ | SRC | P12931 | 3/20 | 0.70 |
| ▸ | EGFR | P00533 | 3/20 | 0.70 |
| ▸ | LYN | P07948 | 3/20 | 0.70 |
| ▸ | SYK | P43405 | 2/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 2/20 | 0.70 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
| ▸ | CSF1R | P07333 | 2/20 | 0.70 |
| ▸ | FGR | P09769 | 2/20 | 0.70 |
| ▸ | BRAF | P15056 | 2/20 | 0.70 |
| ▸ | NQO2 | P16083 | 2/20 | 0.70 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.70 |
| ▸ | FRK | P42685 | 2/20 | 0.70 |
| ▸ | BLK | P51451 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075315 | 0.94 | ABL1 (0.70) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL8191704 | 0.91 | ABL1 (0.72) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL23258781 | 0.90 | ABL1 (0.71) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL10109122 | 0.89 | ABL1 (0.72) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL22844038 | 0.87 | PDGFRA (0.57) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL18561676 | 0.86 | ABL1 (0.60) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL27810491 | 0.85 | ABL1 (0.78) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL16606207 | 0.83 | ABL1 (0.74) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL13524666 | 0.83 | ABL1 (0.73) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.83 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| WO-2011095835-A1 | HIGHLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-11 | — | — | WO | claimed |
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | disclosed |
| CN-110559443-A | composition comprising histamine release-promoting substance and pyridylpyrimidine amine compound, and oral solid preparation containing the same | 黄泳华 | 2019-12-13 | — | — | CN | disclosed |
| WO-2011095835-A1 | HIGHLY PURE IMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-11 | — | — | WO | disclosed |